These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 2870753)

  • 1. A randomised controlled trial of prophylactic neuroleptic treatment.
    Crow TJ; MacMillan JF; Johnson AL; Johnstone EC
    Br J Psychiatry; 1986 Feb; 148():120-7. PubMed ID: 2870753
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Short-term outcome in trial entrants and trial eligible patients.
    MacMillan JF; Crow TJ; Johnson AL; Johnstone EC
    Br J Psychiatry; 1986 Feb; 148():128-33. PubMed ID: 2870754
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low serum neuroleptic levels predict relapse in schizophrenic patients.
    Brown WA; Laughren T; Chisholm E; Williams BW
    Arch Gen Psychiatry; 1982 Sep; 39(9):998-1000. PubMed ID: 6126172
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prophylactic effect of neuroleptics in symptom-free schizophrenics.
    Nishikawa T; Tsuda A; Tanaka M; Koga I; Uchida Y
    Psychopharmacology (Berl); 1982; 77(4):301-4. PubMed ID: 6127747
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Scottish First Episode Schizophrenia Study. II. Treatment: pimozide versus flupenthixol. The Scottish Schizophrenia Research Group.
    Br J Psychiatry; 1987 Mar; 150():334-8. PubMed ID: 2889495
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patient-oriented randomisation: A new trial design applied in the Neuroleptic Strategy Study.
    Schulz C; Timm J; Cordes J; Gründer G; Mühlbauer B; Rüther E; Heinze M
    Clin Trials; 2016 Jun; 13(3):251-9. PubMed ID: 27016729
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Comparative studies of the effects of perazine, fluphenazine, trifluoperazine, chlorpromazine and haloperidol on primary and deficit symptoms of paranoid schizophrenia].
    Termińska K; Mrowiec W
    Psychiatr Pol; 1989; 23(1):24-30. PubMed ID: 2573098
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Scottish first episode schizophrenia study. VII. Two-year follow-up. Scottish Schizophrenia Research Group.
    McCreadie RG; Wiles D; Grant S; Crockett GT; Mahmood Z; Livingston MG; Watt JA; Greene JG; Kershaw PW; Todd NA
    Acta Psychiatr Scand; 1989 Dec; 80(6):597-602. PubMed ID: 2694767
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative study of schizophrenic patients relapsed on and off medication.
    Bartkó G; Mayláth E; Herczeg I
    Psychiatry Res; 1987 Nov; 22(3):221-7. PubMed ID: 2893403
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pimozide for schizophrenia or related psychoses.
    Mothi M; Sampson S
    Cochrane Database Syst Rev; 2013 Nov; (11):CD001949. PubMed ID: 24194433
    [TBL] [Abstract][Full Text] [Related]  

  • 11. How high is the relapse rate in schizophrenia?
    Johnstone EC; Geddes J
    Acta Psychiatr Scand Suppl; 1994; 382():6-10. PubMed ID: 7916528
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Duration of neuroleptic treatment and relapse rate: a 5-year follow-up study with haloperidol decanoate.
    Youssef HA
    Clin Neuropharmacol; 1991; 14 Suppl 2():S16-21; discussion S22-3. PubMed ID: 1684308
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Flupenthixol in chronic schizophrenic inpatients: a controlled comparison with haloperidol.
    Ehmann TS; Delva NJ; Beninger RJ
    J Clin Psychopharmacol; 1987 Jun; 7(3):173-5. PubMed ID: 3298328
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trial of brief intermittent neuroleptic prophylaxis for selected schizophrenic outpatients: clinical outcome at one year.
    Jolley AG; Hirsch SR; McRink A; Manchanda R
    BMJ; 1989 Apr; 298(6679):985-90. PubMed ID: 2567190
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trial of maintenance therapy in schizophrenia.
    Leff JP; Wing JK
    Br Med J; 1971 Sep; 3(5775):599-604. PubMed ID: 4936538
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trial of brief intermittent neuroleptic prophylaxis for selected schizophrenic outpatients: clinical and social outcome at two years.
    Jolley AG; Hirsch SR; Morrison E; McRink A; Wilson L
    BMJ; 1990 Oct; 301(6756):837-42. PubMed ID: 2282421
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Predicting the effect of psychopharmacotherapy in schizophrenic patients].
    Dikiĭ NT
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1982; 82(1):110-5. PubMed ID: 6121436
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Continuation ECT in treatment-resistant schizophrenia: a controlled study.
    Chanpattana W; Chakrabhand ML; Sackeim HA; Kitaroonchai W; Kongsakon R; Techakasem P; Buppanharun W; Tuntirungsee Y; Kirdcharoen N
    J ECT; 1999 Sep; 15(3):178-92. PubMed ID: 10492856
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neuroleptic-induced reductions in serum dopamine-beta-hydroxylase in schizophrenia.
    Goodnick PJ; Tong C; Duncavage MB; Meltzer HY
    Biol Psychiatry; 1983 Dec; 18(12):1485-8. PubMed ID: 6140962
    [No Abstract]   [Full Text] [Related]  

  • 20. Depot flupenthixol decanoate for schizophrenia or other similar psychotic disorders.
    Quraishi S; David A
    Cochrane Database Syst Rev; 2000; (2):CD001470. PubMed ID: 10796442
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.